Over the past few weeks, BARDA reviewed 22 MRNA vaccine development investments and began canceling them. Let me explain why. Most of these shots are for flu or Covid. But as the pandemic showed us, MRNA vaccines don't perform well against viruses that infect the upper respiratory tract. Here's the problem. MRNA only codes for a small part of the viral proteins, usually a single antigen. One mutation, and the vaccine becomes ineffective. (00:38–00:45)
CLAIM
Asserts that MRNA vaccines are ineffective against upper respiratory tract viruses.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
